Siodatinib-11
Description_Effects
Siodatinib-11 contains Tofacitinib 11 mg, an advanced oral Janus kinase (JAK) inhibitor used in the treatment of several chronic autoimmune and inflammatory conditions. It is prescribed for patients suffering from moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, particularly in those who do not respond adequately to conventional disease-modifying antirheumatic drugs (DMARDs). Tofacitinib works by selectively inhibiting the JAK enzymes, which play a crucial role in the inflammatory signaling pathways of the immune system. By blocking these pathways, Siodatinib-11 reduces inflammation, relieves pain and swelling, and helps prevent further joint and tissue damage. In ulcerative colitis, it helps reduce bowel inflammation, frequency of stools, and associated abdominal discomfort. Siodatinib-11 provides a convenient oral alternative to injectable biologics, offering high efficacy with easy administration. It is particularly valued for its rapid onset of action, often showing improvement in symptoms within weeks of initiation. Manufactured to high pharmaceutical standards, Siodatinib-11 ensures consistent potency, safety, and therapeutic performance. Siodatinib-11 – Targeted Immune Modulation for Lasting Relief in Autoimmune Disorders. Empowering patients with a reliable oral solution for chronic inflammatory disease management.
